Migliore Alberto, Gigliucci Gianfranco, Alekseeva Lyudmila, Bannuru Raveendhara R, Blicharski Tomasz, Diracoglu Demirhan, Georgiadis Athanasios, Hamoud Hesham, Martusevich Natalia, Matucci Cerinic Marco, Perduk Jan, Szerb Imre, Trč Tomáš, Chevalier Xavier
Rheumatology Unit - San Pietro Fatebenefratelli Hospital, Rome, Italy.
Department of Metabolic Diseases of Bone and Joints, V.A. Nasonova Research Institute of Rheumatology, Moscow, Russian Federation.
Orthop Res Rev. 2021 Dec 2;13:255-273. doi: 10.2147/ORR.S336185. eCollection 2021.
Osteoarthritis (OA) is a significant cause of disability. Considering the increasing diffusion of the viscosupplementation (VS) with hyaluronic acid (HA), the International Symposium Intra Articular Treatment (ISIAT) appointed a Technical Expert Panel (TEP) to identify the criteria for successful VS with a specific HA in OA; this through a systematic literature review (SLR), performed following the PRISMA guidelines interrogating Medline, Embase, Cochrane Library, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Grey Matters and American College of Rheumatology (ACR/EULAR) databases and the opinion of international experts. The research included only studies on adults and humans without limitations of language or time of publication. Researchers extracted both quantitative and qualitative data from each study. Mixed Methods Appraisal Tool (MMAT) was used to perform quality analysis for the level of evidence. The SLR retrieved 385 papers, 25 of which were suitable for the analysis. The TEP focused on the different formulations of the product Sinovial [HA 0.8%, HA 1.6%, HA 2%, 800-1200 kDa, HA 3.2% (1400-2100 kDa/65-110 kDa)]. The choice was due to the vast amount of evidence available. The TEP weighed the evidence in two rounds of a Delphi survey; the results, and any disagreement, were discussed in a final session. Three domains were considered: 1) the patients' characteristics associated with the best results; 2) the contraindications and the conditions linked to increased risk of failure; 3) the clinical conditions in which VS is considered appropriate. The TEP concluded that VS with HA is safe and effective in the treatment of knee and hip OA of grades I to III and that it is possible to undertake VS in other situations (eg grade IV Kellgren-Lawrence - KL); a comprehensive examination of the patient should be performed before the procedure.
骨关节炎(OA)是导致残疾的一个重要原因。鉴于透明质酸(HA)关节内注射补充疗法(VS)的应用日益广泛,国际关节内治疗研讨会(ISIAT)任命了一个技术专家小组(TEP),以确定在OA中使用特定HA进行成功VS的标准;这是通过一项系统文献综述(SLR)来完成的,该综述按照PRISMA指南进行,检索了Medline、Embase、Cochrane图书馆、护理学与健康相关文献累积索引(CINAHL)、灰色文献以及美国风湿病学会(ACR/EULAR)数据库,并征求了国际专家的意见。该研究仅纳入了关于成年人和人类的研究,没有语言或发表时间的限制。研究人员从每项研究中提取了定量和定性数据。使用混合方法评估工具(MMAT)对证据水平进行质量分析。SLR检索到385篇论文,其中25篇适合进行分析。TEP重点关注了产品Sinovial的不同配方[HA 0.8%、HA 1.6%、HA 2%、800 - 1200 kDa、HA 3.2%(1400 - 2100 kDa/65 - 110 kDa)]。做出这一选择是因为有大量可用证据。TEP通过两轮德尔菲调查对证据进行了权衡;结果以及任何分歧在最后一次会议上进行了讨论。考虑了三个领域:1)与最佳结果相关的患者特征;2)与失败风险增加相关的禁忌症和情况;3)认为VS合适的临床情况。TEP得出结论,HA关节内注射补充疗法在治疗I至III级膝关节和髋关节OA方面是安全有效的,并且在其他情况下(如IV级凯尔格伦 - 劳伦斯分级 - KL)也可以进行VS;在进行该操作之前应全面检查患者。